What Is Portal Hypertensive Gastropathy?

Portal hypertensive gastropathy (PHG) is a condition in which the stomach lining develops characteristic changes because of elevated pressure in the portal venous system. It shows up in a large share of people with liver cirrhosis and portal hypertension, and its hallmark appearance under endoscopy is a mosaic or snakeskin-like pattern on the stomach’s inner surface, sometimes dotted with cherry-red spots. While dramatic bleeding episodes from PHG are uncommon, the condition quietly causes chronic blood loss that can lead to iron-deficiency anemia, making it more clinically important than its understated symptoms might suggest.

What Happens Inside the Stomach Wall

Portal hypertension is a prerequisite for PHG, but having elevated portal pressure does not guarantee the condition will develop. Many people with portal hypertension never show signs of PHG at all. The condition becomes more likely as portal hypertension worsens, as liver disease advances, and when esophageal varices are present.¹ So portal hypertension is necessary, but it is not the whole story.

The underlying mechanism involves what doctors call a hyperdynamic circulation: increased resistance to blood flow through the liver pushes more blood into the splanchnic (gut) circulation, and that extra flow reaches the stomach. Research measuring blood flow directly in the stomach has found that the mucosa of the upper stomach, particularly the fundus, becomes congested and highly perfused in people with PHG, while blood flow in the lower stomach stays closer to normal.² This combination of congestion and excess blood flow in the upper stomach makes the lining fragile and prone to slow, ongoing bleeding.

One counterintuitive finding from hemodynamic studies is that overall portal venous pressure does not differ dramatically between cirrhosis patients who develop PHG and those who do not. What does differ is the pressure gradient between the portal vein and the esophageal varices. That gradient tends to be higher in people who go on to develop PHG, suggesting that how portal pressure distributes through the vascular system matters more than the absolute number.³

Grading and What Endoscopy Reveals

PHG is diagnosed visually during upper endoscopy. The classic mild form shows a mosaic or snakeskin mucosal pattern, while more severe disease adds flat or raised red spots, sometimes described as cherry-red marks, that indicate areas of more intense congestion and fragility. Several classification systems exist, including the McCormack, NIEC, and Baveno criteria, though agreement among endoscopists using these systems is not always strong.⁴ PHG can appear in up to about 65% of people with cirrhosis and portal hypertension.⁵

The severity grade matters because it tracks closely with the degree of portal pressure elevation. One study measuring hepatic venous pressure gradient (HVPG) found that people with severe PHG had a mean gradient of about 15.6 mmHg, compared to roughly 10.7 mmHg in those with mild PHG and just under 5 mmHg in those without it.⁶ Increasing PHG severity also tracks with higher overall liver disease scores (MELD), a greater likelihood of having varices, and elevated markers of systemic inflammation.⁷ In other words, more severe PHG is not just a local stomach problem; it reflects worse liver disease overall.

Chronic Bleeding and Iron-Deficiency Anemia

The most common clinical consequence of PHG is not a sudden, dramatic bleed. Instead, it is a slow, steady ooze from the fragile stomach lining that the patient may not even notice. Over time, this occult blood loss depletes iron stores and leads to iron-deficiency anemia. Estimates suggest that chronic PHG bleeding causes this type of anemia in roughly 3 to 26% of affected patients, depending on severity and how the study population is defined.⁸

In people with severe PHG, the numbers are more striking. One study found that nearly half of patients with severe PHG had iron-deficiency anemia, compared to about a quarter of those with mild PHG and fewer than one in five of those without PHG. Hemoglobin levels averaged around 11.2 g/dL in the severe group versus 13.0 g/dL in those without PHG.⁹ This slow-drip anemia can become transfusion-dependent in some cases, adding significantly to the burden of managing advanced liver disease.

Acute, fulminant bleeding from PHG does happen, but it is rare. When it does occur, it can be difficult to manage because the bleeding tends to be diffuse rather than from a single identifiable vessel, which makes standard endoscopic techniques like clipping or injection less effective.¹⁰

Telling PHG Apart from Gastric Antral Vascular Ectasia

A condition that is easily confused with PHG is gastric antral vascular ectasia, often called GAVE or “watermelon stomach” because of the striped pattern of dilated vessels visible on endoscopy. The two can coexist, and both cause gastric bleeding in people with liver disease, but they are fundamentally different conditions with different treatment strategies.

PHG requires portal hypertension by definition and tends to affect the upper stomach (fundus and body). GAVE does not require portal hypertension or even cirrhosis; it can occur in people with autoimmune conditions, kidney disease, or other non-liver causes. It concentrates in the antrum (the lower stomach near the outlet). This distinction matters for treatment: PHG responds to drugs that lower portal pressure, while GAVE responds to endoscopic ablation techniques that destroy the abnormal vessels.¹¹ Misidentifying one as the other can send treatment in the wrong direction.

PHG Without Cirrhosis

Although cirrhosis is the most common underlying condition, PHG is not exclusive to it. Any cause of portal hypertension can produce the same stomach mucosal changes. These include non-cirrhotic portal hypertension (sometimes called idiopathic portal hypertension), portal vein thrombosis or obstruction, and Budd-Chiari syndrome, where blood flow out of the liver is blocked at the hepatic vein level.¹² When PHG shows up in someone without known cirrhosis, it should prompt investigation into these alternative causes of portal hypertension.

An additional factor that may worsen PHG in people who already have cirrhosis is Helicobacter pylori infection. In one study of 70 cirrhotic patients with PHG, 44% tested positive for H. pylori, compared to 27% of matched cirrhotic patients without PHG. The association was even more pronounced in severe PHG: among H. pylori-positive patients who had PHG, most had the severe form, while H. pylori-negative patients with PHG more often had the mild version.¹³ Whether treating H. pylori improves PHG in this setting remains an open question, but the association is strong enough to warrant testing.

Can PHG Be Detected Without Endoscopy?

Endoscopy is the only reliable way to diagnose PHG right now. Researchers have hoped to find blood tests or imaging measurements that could predict who has PHG without needing to pass a scope, especially since many people with cirrhosis already undergo frequent procedures. Unfortunately, commonly used fibrosis markers have shown poor ability to identify PHG or to distinguish it from varices alone.¹⁴

Some ultrasound-based measures have shown moderate promise. A study in Egyptian cirrhosis patients found that portal vein diameter greater than 10.5 mm, the ratio of platelet count to spleen diameter, and the ratio of right liver lobe diameter to albumin level were each independently associated with PHG and performed reasonably well as predictors.¹⁵ These are useful screening tools that could help prioritize which patients most need endoscopy, but none are accurate enough to replace it. For the foreseeable future, if PHG needs to be confirmed, a scope is the way to do it.

Treatment Approaches

Because PHG is driven by portal hypertension, the first-line treatment targets the pressure itself rather than the stomach directly. Non-selective beta-blockers like propranolol and carvedilol reduce portal pressure by decreasing cardiac output and constricting the splanchnic arteries. Carvedilol appears to lower portal pressure somewhat more effectively than propranolol.¹⁶ For many patients with mild PHG and slow chronic bleeding, a beta-blocker is all that is needed.

When acute bleeding from PHG does occur, drug therapy focuses on reducing splanchnic blood flow quickly. In a controlled trial comparing octreotide, vasopressin, and omeprazole for acute PHG bleeding, octreotide achieved complete bleeding control in all patients within 48 hours, compared to about 64% for vasopressin and 59% for omeprazole. Octreotide also required less time and fewer blood transfusions to achieve control.¹⁷ Omeprazole, a proton pump inhibitor commonly used for acid-related stomach problems, is relatively ineffective here because PHG bleeding is driven by vascular congestion rather than acid erosion.

Endoscopic Options

Argon plasma coagulation (APC) is an endoscopic technique that uses a jet of ionized argon gas to cauterize bleeding tissue without direct contact. It has shown genuine promise for PHG, particularly when beta-blockers are contraindicated or insufficient. In a study of 89 patients with PHG in the fundus or body of the stomach, about three-quarters achieved complete bleeding control after a single APC session. Patients with more widespread disease involving the entire stomach needed multiple sessions but still achieved control.¹⁸ The combination of APC with a beta-blocker may have additive benefits.

A head-to-head comparison of APC versus carvedilol alone found that both approaches improved iron-deficiency anemia over time, but the improvement in hemoglobin, serum iron, and serum ferritin was significantly greater in the APC group.¹⁹ APC is not a cure for the underlying portal hypertension, but it can buy time by stopping the mucosal bleeding that drives anemia.

TIPS as Salvage Therapy

When medications and endoscopic approaches fail to control bleeding, a transjugular intrahepatic portosystemic shunt (TIPS) becomes an option. TIPS is a procedure performed by interventional radiologists in which a small channel is created within the liver to reroute portal blood flow directly into the hepatic veins, bypassing the congested liver tissue and sharply reducing portal pressure. It is considered salvage therapy for refractory PHG.²⁰ ²¹ TIPS is effective at lowering portal pressure, but it carries its own risks, including hepatic encephalopathy (confusion from toxins that the shunt diverts past the liver) and shunt dysfunction over time.

How Variceal Treatment Can Make PHG Worse

An irony of managing portal hypertension is that treating one complication can aggravate another. Endoscopic band ligation, the standard procedure for treating esophageal varices, has been shown to worsen PHG. The mechanism makes intuitive sense: obliterating the varices redirects blood flow elsewhere in the portal system, and some of that flow ends up increasing congestion in the stomach lining. A prospective trial found that band ligation of esophageal varices accentuated gastropathy, though adding propranolol partly offset this effect.²²

This connection is one reason clinicians monitor patients closely after variceal banding. A patient who had no PHG before a ligation session may develop it afterward, or a patient with mild PHG may find it progressing to the severe form. Beta-blockers serve double duty in this context, helping to prevent both variceal rebleeding and the worsening of gastropathy.

PHG as a Marker of Prognosis

Beyond its direct effects on bleeding and anemia, PHG carries prognostic information about overall survival in cirrhosis. In one study tracking patients over several years, those without PHG had a survival rate of 92%, compared to about 79% for those with PHG. When broken down further, patients with severe PHG fared the worst, and the differences were significant even after accounting for the stage of liver disease. In a multivariate analysis, severe PHG carried roughly triple the risk of death compared to having no PHG, independent of Child-Pugh class.²³

This does not mean PHG itself is killing people. It more likely reflects the fact that PHG signals more advanced portal hypertension and worse overall liver function. Still, the finding suggests that when a gastroenterologist sees severe PHG on endoscopy, it should inform broader management decisions, including how urgently to consider liver transplant evaluation.

The Inflammation Angle

Recent research has added another dimension to understanding PHG by linking it to systemic inflammation. A study examining inflammatory markers found that increasing PHG severity tracked with higher levels of interleukin-6 (IL-6), a key inflammatory molecule.²⁴ Advanced cirrhosis is known to produce a state of chronic low-grade inflammation, partly because the damaged liver and leaky gut allow bacterial products to enter the bloodstream. PHG may be both a consequence and a contributor to this inflammatory cycle: the congested, fragile stomach lining could serve as one more surface where bacterial translocation and immune activation occur. Whether targeting inflammation directly could improve PHG outcomes is unknown, but the connection helps explain why PHG tracks so closely with overall disease progression rather than being a purely mechanical consequence of high pressure.